HCPCS Level II J0135: Adalimumab 20 mg Injection
HCPCS Level II code J0135 denotes a 20 mg injection of adalimumab, a TNF-blocking biologic used across multiple inflammatory and autoimmune conditions. Nationally, this code matters because biologic therapies constitute a substantial and growing share of outpatient drug spend and require accurate coding for coverage, billing, and clinical tracking.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer policies, billing benchmarks, and clinical context for use of J0135, with attention to site-of-service implications and documentation needs.
Readers will learn how J0135 is defined and applied in outpatient settings, how major payers approach coverage and reimbursement at a high level, and what benchmarks and policy updates affect billing for adalimumab 20 mg injections. The report also provides clinical context on typical administration settings and summarizes where readers can expect variation in payer handling. Data not available in the input is noted where applicable.
Sign up for hcpcs J0135 policy alerts
Get alerted when payer policies referencing J0135 are released or updated.
Billing Code Overview
HCPCS Level II code J0135 represents an injection of adalimumab, 20 mg. This code is used to report administration of a 20 mg dose of adalimumab, a monoclonal antibody targeting tumor necrosis factor (TNF). The service type is medication injection/biologic drug administration. The typical site of service is outpatient infusion or injection settings such as physician offices, specialty clinics, and outpatient infusion centers.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with an immune‑mediated inflammatory disease such as moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn disease, or hidradenitis suppurativa who presents to an outpatient infusion/injection clinic, specialty pharmacy clinic, or physician office for administration of a prefilled syringe of adalimumab. The clinical workflow begins with verification of the prescription and prior authorization, medication reconciliation and allergy check, assessment of baseline vital signs and infection risk screening (including tuberculosis and recent infections), patient education on expected effects and adverse reactions, and documentation of lot number and expiration. The medication J0135 (injection, adalimumab, 20 mg) is obtained from pharmacy, labeled, and administered subcutaneously by a registered nurse or licensed medical personnel. Observation for acute hypersensitivity or injection‑site reaction occurs for a short period (typically 15–30 minutes) after injection. Documentation includes indication, medication name and dose, route, site, lot number, NDC when required, and any immediate adverse events. Billing includes the HCPCS Level II code J0135 and may include relevant modifiers for unusual circumstances or payer requirements.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work, time, or intensity substantially exceeds typical for adalimumab injection and documentation supports additional resources. |
23 | Unusual anesthesia | Rarely used for this injection; apply only when general anesthesia or monitored anesthesia care is required for the procedure and documented. |
52 | Reduced services | Use when adalimumab injection was started but not completed and service was partially reduced. |
53 | Discontinued procedure | Use when the injection service is terminated prior to completion for patient safety reasons. |
54 | Surgical care only | Not typically applicable but used when only the surgical portion is provided by this provider and postoperative care is transferred. |
55 | Postoperative management only | Not typical for injections; use if provider only performs post‑procedure management related to injection. |
56 | Preoperative management only | Use if provider only furnished preoperative management related to an injectable procedure. |
62 | Two surgeons | Rare for this service; use when two surgeons are required and documented for an associated procedure. |
AS | Physician assistant, nurse practitioner, or clinical nurse specialist services for surgical assist | Apply when appropriate assistant services are furnished in conjunction with an associated procedure. |
CO | Cast application | Not applicable to injection; include only if an associated procedure requiring cast occurred. |
CQ | Service delivered under an outpatient PE program (distinctive payor programs) | Use when required by payer program rules for clinical trial or specialized outpatient programs, if applicable and documented. |
FX | Primary surgeon | Use in multi‑surgeon reporting when identifying the primary surgeon; rarely relevant to adalimumab injection alone. |
FY | Secondary surgeon | Use in multi‑surgeon reporting when identifying a secondary surgeon; rarely relevant. |
QK | Medical direction of two, three, or four assistants | Use when the physician directs multiple assistants during an associated procedure. |
QX | CRNA service with medical direction by physician | Use when CRNA services are provided under direction; not typical for routine injection but applicable if anesthesia is required. |
QY | Medical direction of one CRNA by an anesthesiologist | Use when applicable for anesthesia services tied to the visit. |
SH | Physician assistant services incident to physician | Use when services are furnished by a physician assistant under supervision as incident to the physician's services. |
SJ | Nurse midwife services incident to physician | Use when a certified nurse‑midwife provides services incident to physician. |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
207RC0000X | Rheumatology | Rheumatologists commonly prescribe and oversee adalimumab therapy for inflammatory arthritis. |
208000000X | Internal Medicine | Hospitalists and internists may administer or manage biologic therapy in outpatient clinics. |
207L00000X | Allergy & Immunology | Allergists manage biologic therapy for certain immune‑mediated conditions and evaluate hypersensitivity risks. |
363LF0000X | Nurse Practitioner | Nurse practitioners frequently administer injections and provide patient education in specialty clinics. |
367A00000X | Physician Assistant | Physician assistants perform injections and follow‑up care under supervising physician protocols. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
M06.9 | Rheumatoid arthritis, unspecified | Rheumatoid arthritis is a common indication for adalimumab therapy to control synovitis and prevent joint damage. |
L40.0 | Psoriasis vulgaris | Moderate to severe plaque psoriasis is treated with adalimumab to reduce skin lesions and inflammation. |
L40.5 | Arthropathic psoriasis | Psoriatic arthritis indications overlap with psoriasis and require TNF inhibitor therapy such as adalimumab. |
M07.0 | Distal interphalangeal psoriatic arthropathy | Specific psoriatic arthritis presentations commonly treated with biologics including adalimumab. |
K50.00 | Crohn disease of small intestine without complications | Crohn disease is an approved indication for adalimumab to induce and maintain remission. |
K51.90 | Ulcerative colitis, unspecified, without complications | Ulcerative colitis may be treated with adalimumab for moderate to severe disease. |
L73.2 | Hidradenitis suppurativa | Moderate to severe hidradenitis suppurativa is an indication for adalimumab therapy. |
M45.9 | Ankylosing spondylitis, unspecified | Axial spondyloarthritis and ankylosing spondylitis are indications where adalimumab is used to reduce inflammation and improve function. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
96372 | Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | Commonly used to report the administration service for a subcutaneous injection like adalimumab when payer requires a separate administration code in addition to the drug HCPCS J0135. |
99001 | Handling and/or processing of a drug or biological for patient administration, per dose (example placeholder — verify payer list) | Some facilities use specific facility or local codes for drug handling; verify payer policy. (Note: use only if recognized by the payer.) |
96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | Not typical for subcutaneous adalimumab but included when an infusion encounter with separate infusion services occurs concurrently. |
36415 | Collection of venous blood by venipuncture | Often performed prior to biologic initiation for baseline labs (CBC, CMP, TB testing) supporting therapy with adalimumab. |
99406 | Smoking and tobacco use cessation counseling visit, intermediate | Counseling codes commonly used during chronic disease management visits where lifestyle counseling is provided alongside biologic therapy. |